Articles, guides, and regulatory updates from our community.
New research explores how GLP-1 receptor agonists affect skin biology, inflammation, wound healing, and aesthetic aging. Learn what the evidence shows.
By Peptide Association Research Team
New research across 85 trials finds incretin-based therapies modestly reduce blood pressure and lower mortality in adults with obesity. Read the evidence.
By Peptide Association Research Team
New research explores retatrutide's role in CKM syndrome, showing significant weight loss, glycemic control, and cardiorenal benefits in Phase 2 trials.
By Peptide Association Research Team
New research on retatrutide shows promising weight loss and metabolic results. Learn what the 2026 clinical review found about this triple hormone receptor agonist.
By Peptide Association Research Team
New research identifies a novel chemical impurity in compounded tirzepatide/B12 products. Learn what this means for patient safety and informed treatment decisions.
By Peptide Association Research Team
The GLP-1 revolution has rewritten the rules of obesity treatment. How incretin-based peptide therapies achieve what diet and exercise alone cannot — and what comes next.
By Peptide Association Editorial Team
A head-to-head comparison of the two leading GLP-1 receptor agonists — mechanisms of action, clinical trial data, side effects, and practical considerations for providers and patients.
By Peptide Association Editorial Team